A case is described of chronic mucocutaneous candidiasis (CMC) with polyendocrinopathy, folate deficiency and a serum-dependent phagocytic candida killing defect. In contrast with systemic candidiasis (Staples et al. 1977) , phagocytic function has been reported to be normal in most patients with CMC, and it has been suggested that this could account for the striking absence of invasive candida infections in these patients. However, a serum-dependent defect in phagocytic killing of Candida albicans by monocytes has recently been demonstrated in 2 out of S patients with CMC ( Van der Meer et al. 1978) . In the present case, after repeated failure of topical therapies combined with folic acid supplements, eradication of candida was achieved and maintained with ketoconazole (Janssen), a new orally-active antifungal agent. The phagocytic defect reverted to normal during therapy and no adverse effects were noted.
Case report
A 27-year-old white female first noticed thickening, distortion, discolouration and shortening of her finger nails when aged 9 ( Figure  I ). Candida albicans has been recovered on many occasions from the nails and subsequently affected sites. During her teens she developed persistant candidal stomatitis, angular cheilitis and involvement of the palms and soles (Figure 2 ). Since the age of 21 she has had candidal vulvovaginitis, and when aged 2S she had an episode of candidal oesophagitis which responded to nystatin. Otherwise, anticandida therapy has been ineffective.
When aged 16 she had a cardiac arrest during an appendicectomy. Minimal but typical pigmentaion of Addison's disease was present but its significance had not been appreciated. Hypoadrenocorticalism was confirmed biochemically and since then she has been on replacement doses of hydrocortisone and fludrocortisone.
Her menarche began at the age of II but she developed secondary amenorrhoea S years later. Levels of follicle-stimulating hormone and luteinizing hormone were grossly elevated, and progesterone and oestriol levels were subnormal. An ovarian biopsy showed only occasional primordial follicles. To date there has been no evidence of hypoparathyroidism, thyroid disease, pernicious anaemia or diabetes mellitus and serum iron and iron-binding capacity have been normal on several occasions. In 1978 she was shown to have low serum and red cell folate levels, without anaemia or macrocytosis. She refused further investigations to determine the cause of this folate deficiency. Folic acid supplements have restored the low levels to normal but have had no effect on her candida infection.
In the past she has had septicaemia (aged 6 months), infectious hepatitis (aged II) and pyelonephritis (aged 18). There is no known consanguinity in her family. She had 4 siblings, one of whom died of infectious hepatitis at the age of 7. Sera from her parents and remaining siblings have been screened for autoantibodies. One sister had high titres of ANF and thyroid microsomal antibodies.
Immunological studies: Immunological assessment was performed prior to starting ketoconazole therapy. Skin testing with candida antigen (Bencard 1%) gave a strongly positive haemorrhagic reaction at 5 hours, persisting beyond 48 hours. There was also a strong, delayed skin reaction to streptokinase-streptodornase (Lederle) and the patient readily became sensitized to dinitrochlorobenzene. The following were also normal: T and B lymphocyte blood counts; in vitro lymphocyte responses to phytohaemagglutinin, concanavalin A, purified protein derivative and C. albicans; serum complement (CH sQ, C 3 and C 4 ) and serum immunoglobulins. including IgE.
She had a high titre of complement fixing antibodies to C. albicans in keeping with the strong Arthus-type skin response. There were high titres of autoantibodies reacting with all layers of the adrenal cortex, granulosa cel1s of the ovary, interstitial cel1s of the testis and gastric parietal cel1s, but other autoantibodies could not be detected. The ability of the patient's phagocytes to kil1 C. albicans was tested by a radiometric method (Bridges et al.1980) . As can be seen in Table I , the patient's neutrophil leukocytes showed subnormal killing capacity when tested on two occasions in autologous serum, while their candidacidal activity was normal in the presence of serum from healthy control subjects. Similarly, the patient's serum failed to support killing by neutrophils from healthy controls. There were no adverse effects clinically, and no abnormalities were seen from monthly screening of full routine blood counts, liver and renal function tests and blood lipids. Her immunological status was re-evaluated in April 1980 and there was no longer any defect in neutrophil candida killing (Table 2) .
Progress during treatment:
In June 1980 the ketoconazole treatment was stopped for 2 weeks. Oral and vaginal infection Her phagocytic function was tested towards the end of the second week and again her cells showed subnormal ability to kill C. albicans in autologous serum, although her serum supported normal killing by control neutrophils on this occasion (Table 2 ). There was prompt clinical recovery when the ketoconazole treatment was resumed and the patient has remained free of infections to date on this treatment.
Discussion
CMC is characterized by refractory candida infection of mucous membranes, skin and nails without systemic involvement. In terms of pathophysiology it is probably not a single disease entity, and the candida infection seems to reflect a final common pathway for several predisposing abnormalities which may vary in different patients. Several subgroups have been defined using clinical and genetic criteria, and in the classification of Higgs & Wells (1972) patients with one or more endocrine abnormalities constituted a distinct subgroup, usually with autosomal recessive inheritance. The present case demonstrates that endocrine deficiency may develop many years after the onset of candida infection and present with a dramatically sudden onset. The associated endocrine disorders include hypoparathyroidism, Addison's disease, and less commonly hypothyroidism, diabetes mellitus, pernicious anaemia and ovarian insufficiency. Other manifestations include chronic active hepatitis; and steatorrhoea has been described (Mackey 1975) . Iron deficiency is a common association and occasionally there are reduced levels of vitamin A, folate and pyridoxin. Correction of these nutritional deficiencies has been associated with clinical improvement in some cases (Higgs & Wells 1972 , 1973 .
Various autoantibodies can often be demonstrated in affected individuals and in members of their families, and abnormal immunoregulation involving defective suppressor T cell function was recently reported in a family with candidiasis and polyendocrinopathy (Arulanantham et al. 1979) .
CMC patients have also been categorized according to the nature of their immunological defect, which most commonly involves cell mediated immunity (Valdimarsson et al. 1973) , but correction of these defects does not always lead to clearance of the candida infection (Hitzig & Grob 1974) . Most CMC patients have normal T lymphocyte numbers and responses to nonspecific lymphocyte mitogens and antigens other than candida, but a few are anergic to all common skin test antigens, and lymphocytes from such patients usually fail to produce migration inhibitory factor (MIF) in vitro. However, a selective lack of delayed hypersensitivity to candida can be The nature of this abnormality remains to be elucidated. From preliminary experiments in which the patient's serum was mixed with normal sera it is most unlikely that the defect is due to the presence of an inhibitor (data not shown). It has recently been demonstrated that C 3 complement, in addition to its opsonic activity, also participates directly in phagocytic killing of C. albieans (Yamamura & Valdimarsson 1977) . This activity should be distinguished from opsonization, and the term 'procidin' has therefore been proposed for humoral substances which directly increase the susceptibility of microorganisms to the action of intracellular killing mechanisms (Valdimarsson & Yamamura 1979) . The patient presented here had a normal serum level of C 3 measured immunochemically, but neither a functional C 3 abnormality nor defective C 3 activation has been excluded. It is also possible that serum components other than C 3 may have procidin function.
It should be noted that the patient's serum has normal procidin activity during the ketoconazole treatment. This drug has antifungal activity in vivo at a much lower concentration than is effective in vitro (Dixon et al. 1978) . It is therefore possible that ketoconazole acts as a procidin in vivo, either alone or in combination with a serum component, and a preliminary study supports this possibility (Bridges & Valdimarsson, unpublished) .
The introduction of this orally active imidazole compound appears to be a major advance in the treatment of all forms of candidiasis. Previously available anticandida agents all have major drawbacks: amphotericin Band miconazole must be given intravenously, c1otrimazole is unacceptably toxic, and resistance to 5-fluorocytosine commonly develops.
Preliminary studies suggest that ketoconazole is of great potential value in chronic mucocutaneous candidiasis. Out of 12 patients treated by Hay et al. (1980) , remission of oral candidiasis was seen in II after 3-6 weeks of therapy and there was substantial improvement of the nail infection in 10. Subsequently, eradication of nail candidiasis has been achieved in 8 patients after 5-10 months therapy. Partial responses to treatment were seen in 3 patients with, respectively, accompanying dermatophytosis, leucoplakia and gross destruction of the nail plate. After stopping ketoconazole, 2 patients had a relapse of oral candidiasis which responded promptly to reinstitution of ketoconazole therapy for 1-2 weeks. Throughout the period of study no side effects were noted apart from mild nausea in one patient, and there was no evidence of either drug resistance or enhanced drug metabolism. The good response to ketoconazole seen in the present patient is further evidence of the efficacy of the drug given for prolonged periods in· chronic candida infections.
Ketoconazole has also been used for dermatophytosis, paracoccidioidomycosis and some other forms of deep mycosis. Adverse reactions appear to be infrequent and mild and acquired resistance of susceptible organisms has not been reported. Van Ticrynafen (known as tienilic acid in Europe), a newly synthesized agent. appeared to be a useful new antihypertensive drug because of its unique combination of diuretic, antihypertensive, and hypouricaemic effects. This agent has not proved to be an unmixed blessing. Recently. the manufacturers withdrew the drug from the market because five patients died while they were on ticrynafen therapy.
In an editorial. Barclay (1980) commented that these deaths may, of course. have been unrelated to the drug. and a careful re-evaluation of ticrynafen may lead to its reintroduction. Physicians should. however be thoroughly familiar with the adverse effects of this agent should it be reintroduced. Recognition of drugdrug interactions is of vital importance as it may prevent serious complications and hence result in better clinical judgment. Weber & Fishman (1979) described a patient taking both ticrynafen and phenytoin who showed signs of phenytoin toxicity. Ticrynafen was discontinued and gradual resolution of the symptoms took place over the ensuing weeks.
A case is now reported of acute cerebellar syndrome due to ticrynafen-induced phenytoin toxicity, which completely resolved on withdrawal of ticrynafen.
Case report
In 1972a 37-year-old white man was diagnosed as having grand mal epilepsy of undetermined aetiology. He was started on phenobarbitone 15 mg three times a day. This proved insufficient, and in 1973 phenytoin 300 mg daily was added to his regime. His seizure disorder has been well under control, with serum phenytoin levels in ' therapeutic range. In early September 1979, ticrynafen 250 mg a day was instituted to control his blood pressure and hyperuricaemia. After three weeks of treatment with ticrynafen, he began to experience tremors in the right arm, severe aches and pains in both thighs and arms, severe headaches, extreme restlessness, paraesthesia of the lower extremities, unsteadiness, syncopal attacks, confusion and depression. His wife noticed that he was apathetic and would 'sob like a baby. ' By the fourth week of ticrynafen treatment, the patient also had slurred speech, marked difficulty in walking and profuse mental confusion. Clinical examination revealed a tearful, and depressed young man with nystagmus, cerebellar ataxia and dysarthria. A presumptive diagnosis of phenytoin toxicity due to an interaction was made and hence ticrynafen was stopped immediately. His wife had already decreased the dose of phenytoin to 100mg daily on the third week of ticrynafen therapy when he started having 'problems'. Complete blood count and SMA-12 profile did not reveal any abnormality. The serum phenytoin level was 30.2 j.tg/ml (one week after phenytoin 100 mg daily).
Marked improvement was noted over the next three weeks when the serum phenytoin level was noted to be 10.2 j.tg/ml. Complete resolution of all the symptoms took place over the next three weeks. I suggest that this patient had central nervous system toxicity related to phenytoin/ticrynafen interaction.
Discussion
Ticrynafen may decrease the excretion of penicillins and aspirin (Medical Letters 0/1 Drugs and Therapeutics 1979) . Anticoagulant potentiation and haemorrhage have been documented when ticrynafen was used concurrently with warfarin (Slattery & Levy 1979) . One patient died shortly after hospitalization, and autopsy disclosed a large retroperitoneal haematoma (McLain et al. 1980) . Acute renal failure, renal stones and hepatotoxicity are well known adverse reactions associated with ticrynafen use (Sawa et al. 1980) .
I believe the present case is the first documented example of the toxic interaction between phenytoin and ticrynafen. Serum phenytoin levels prior to ticrynafen ranged between 5-10 j.tg/ml, and steady state serum phenytoin levels have been in the same range on 300mg/day.
In vitro studies with ticrynafen have shown competition from albumin binding sites. Caution should be exercised when this agent is used concurrently with other drugs, like phenytoin, tolbutamide and warfarin, that are weakly protein bound. Ticrynafen is very highly protein bound, therefore it displaces phenytoin which is weakly
